FCM
AGIO icon

Frontier Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Frontier Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-27,037
Closed -$2.28M – 288
2018
Q2 		$2.28M Sell
27,037
-129,104
-83% -$11.3M 0.02% 285
2018
Q1 		$12.8M Buy
+156,141
New +$12.1M 0.09% 221

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Frontier Capital Management's AGIO Position: Q3 2018 in Review

Frontier Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q3 2018, closing a stake of 27,037 shares — an estimated $2.28M sold.

Frontier Capital Management first reported a position in AGIO in Q1 2018 and held it in 2 quarters. The position peaked at $12.8M in Q1 2018. 208 funds tracked by Wall St. Rank hold AGIO as of Q3 2018.

  • Frontier Capital Management reported no remaining Agios Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Frontier Capital Management sold 27,037 Agios Pharmaceuticals shares in Q3 2018, an estimated $2.28M.
  • Frontier Capital Management first reported a position in Agios Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Frontier Capital Management's Agios Pharmaceuticals position peaked at $12.8M in Q1 2018.
  • 208 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2018.

Based on Frontier Capital Management's 13F filing for Q3 2018, filed 30 Oct 2018.